Vanda Pharmaceuticals Inc... (VNDA)
NASDAQ: VNDA
· Real-Time Price · USD
4.83
-0.07 (-1.43%)
At close: Sep 25, 2025, 3:59 PM
4.82
-0.21%
After-hours: Sep 25, 2025, 04:59 PM EDT
-1.43% (1D)
| Bid | 4.79 |
| Market Cap | 285.4M |
| Revenue (ttm) | 203.47M |
| Net Income (ttm) | -66.94M |
| EPS (ttm) | -1.14 |
| PE Ratio (ttm) | -4.24 |
| Forward PE | -4.86 |
| Analyst | Strong Buy |
| Dividends | n/a |
| Ask | 4.84 |
| Volume | 482,651 |
| Avg. Volume (20D) | 467,625 |
| Open | 4.92 |
| Previous Close | 4.90 |
| Day's Range | 4.78 - 4.92 |
| 52-Week Range | 3.81 - 5.55 |
| Beta | 0.74 |
| Ex-Dividend Date | n/a |
About VNDA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol VNDA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for VNDA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsVanda Pharmaceuticals Inc. is scheduled to release its earnings on
Nov 5, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
11 months ago
+8.33%
Vanda Pharmaceuticals shares are trading higher af...
Unlock content with
Pro Subscription
3 weeks ago · seekingalpha.com
Vanda: Next Phase Of Fanapt Growth Might Be With Bysanti AdvancementVanda Pharma's revenue growth is driven by Fanapt's label expansion to bipolar I disorder, offsetting declines in HETLIOZ and PONVORY sales. Upcoming catalysts include Bysanti's PDUFA date for bipolar...
1 month ago · seekingalpha.com
Vanda Pharmaceuticals Inc. (VNDA) Q2 2025 Earnings Call TranscriptVanda Pharmaceuticals Inc. (NASDAQ:VNDA ) Q2 2025 Earnings Call July 31, 2025 8:00 AM ET Company Participants Kevin Patrick Moran - Senior VP, CFO & Treasurer Mihael H. Polymeropoulos - Founder, Presi...
